Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

Summary: Due to loss of p16ink4a in pancreatic ductal adenocarcinoma (PDA), pharmacological suppression of CDK4/6 could represent a potent target for treatment. In PDA models, CDK4/6 inhibition had a variable effect on cell cycle but yielded accumulation of ATP and mitochondria. Pharmacological CDK4...

Full description

Bibliographic Details
Main Authors: Jorge Franco, Uthra Balaji, Elizaveta Freinkman, Agnieszka K. Witkiewicz, Erik S. Knudsen
Format: Article
Language:English
Published: Elsevier 2016-02-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124715015508

Similar Items

Similar Items